ArticleAJR. American journal of roentgenology2016
Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors.
Article in AJR. American journal of roentgenology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 63 citations in OpenAlex.
- Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.European urology · 2023Trial
- Role of Stereotactic Ablative Radiotherapy in Primary Renal Cell Carcinoma: A Review of Clinical Trials.Indian journal of surgical oncology · 2025Review
- Renal Oncocytoma Treated With Stereotactic Body Radiation Therapy in a Patient With Prior Pancoast Tumor.Cureus · 2025Article
- Stereotactic ablative radiotherapy for primary kidney cancer - An international patterns of practice survey.Clinical and translational radiation oncology · 2025Article
- Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.Life (Basel, Switzerland) · 2024Review
- Delta radiomics to track radiation response in lung tumors receiving stereotactic magnetic resonance-guided radiotherapy.Physics and imaging in radiation oncology · 2024Article
- Treatment Landscape of Renal Cell Carcinoma.Current treatment options in oncology · 2023Review
- Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk.Clinical and translational radiation oncology · 2023Article
- The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.Cancers · 2023Review
- First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer.BJUI compass · 2023Article
- Article
- Review
- Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.Abdominal radiology (New York) · 2021Review
- Article
- Adaptive radiosurgery based on two simultaneous dose prescriptions in the management of large renal cell carcinoma brain metastases in critical areas: Towards customization.Surgical neurology international · 2020Article
- Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.BMC urology · 2019Article
- Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?Clinical and translational radiation oncology · 2019Review
- Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer.Journal of oncology · 2019Review
- Imaging Advances in the Management of Kidney Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe objective of our study was to assess the growth rate and enhancement of renal masses before and after treatment with stereotactic body radiotherapy (SBRT). MATERIALS AND
methodsThis retrospective study included all patients with renal masses who underwent SBRT during a 5-year period. Orthogonal measurements of renal masses were obtained on pre- and posttreatment CT or MRI. Pre- and posttreatment growth rates were compared for renal mass diameter and volume using the t test. Pre- and posttreatment tumor enhancement values were compared for tumors that underwent multiphasic contrast-enhanced MRI.
resultsForty patients underwent SBRT for the treatment of 41 renal tumors: clear cell renal cell carcinomas (RCCs) (n = 16), papillary RCCs (n = 6), oncocytic neoplasms (n = 8), unclassified RCCs (n = 2), urothelial carcinoma (n = 1), and no pathologic diagnosis (n = 8). The mean maximum tumor diameter before treatment was 3.9 cm (range, 1.6-8.3 cm). Three hundred thirty-eight pre- and posttreatment imaging studies were analyzed: 214 MRI studies and 124 CT studies. The mean pre- and posttreatment lengths of observation were 416 days (range, 2-1800 days) and 561 days (83-1366 days), respectively. The mean pretreatment tumor growth rate of 0.68 cm/y decreased to -0.37 cm/y post treatment (p < 0.0001), and the mean tumor volume growth rate of 21.2 cm(3)/y before treatment decreased to -5.35 cm(3)/y after treatment (p = 0.002). Local control-defined as less than 5 mm of growth-was achieved in 38 of 41 (92.7%) tumors. The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 showed progression in one tumor (2.4%), stability in 31 tumors (75.6%), partial response in eight tumors (19.5%), and complete response in one tumor (2.4%). No statistically significant change in tumor enhancement was shown (mean follow-up, 142 days; range, 7-581 days).
conclusionRenal tumors treated with SBRT show statistically significant reductions in growth rate and tumor size after treatment but do not show statistically significant differences in enhancement in the initial (mean, 142 days) posttreatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.